- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05476640
Newborn Sequencing Screening in China
The Application of Targeted Sequencing in the Screening of Neonatal Diseases
Study Overview
Detailed Description
Neonatal screening (NBS) is the last step of birth defects prevention. Currently, biochemical and mass spectrometry are commonly used for NBS, but there are limited diseases and certain false positive/negative. High-throughput sequencing (NGS) has been widely used in prenatal diagnosis, tumor-targeted biomarkers detection and pathogen detection. Although the application of NGS in new screening has a broad prospect and many countries around the world have begun to explore it, there are still challenges in the selection of screening diseases, gene clinical phenotypes, genetic counseling and clinical pathway.
Since 2019, our team began to explore the appllication of NGS technologies in the clinical application of tertiary prevention, combined with Clinva, HGMD, OMIM database, on the basis of screening specific disease-causing genes and mutation sites as the target, A NGS panel for Newborns in China (NeoExome) was designed, covering 542 single-gene diseases with 601 genes. The rationality and validity of the NGS panel was preliminarily verified in 3423 neonatal blood samples collected from 5 new screening centers in China.
In order to further optimize the gene screening spectrum of neonatal diseases in the Chinese population, evaluate the efficacy of targeted sequencing technology in the screening and diagnosis of neonatal diseases, standardize the clinical pathway, and lay a foundation for the formulation of China's new screening NGS guidelines, the investigators further optimized the targeted sequencing package (NeoexOME-V2) on the basis of the first phase. 491 genes covering 485 single-gene genetic diseases were designed to launch the "Budding Action". The project plans to collect 10000 samples nationwide and carry out the multi-center clinical research on the application of targeted sequencing technology in the screening of neonatal diseases.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- -- Subjects: all newborns (from birth to 28 days);
- -- After fully understanding the program, the guardian signs the informed consent and agrees to participate in the program.
Exclusion Criteria:
- Other similar clinical research projects are under way for the examined neonates;
- Neonates have received transfusion of allogeneic blood products;
- Newborns whose guardians explicitly refuse to participate in the program after receiving the mission.
Elimination criteria
- Samples that are not properly collected or stored for testing;
- Samples with non-standard data records;
- Samples without clinical follow-up results;
- The project recalls newborns who are required to withdraw by their guardians during the follow-up.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
National multicenter screening
NGS was performed based on conventional NBS.
The relationship between NGS detected gene variation and disease occurrence was studied through follow-up.
|
In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease incidence among NGS positive participants
Time Frame: 3 years
|
Newborn was followed up for 3 years after birth, and the follow-up results were compared to evaluate and study the relationship between gene variation and disease occurrence
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The consistency of test results of NGS and conventional NBS
Time Frame: 1 year
|
Conventional NBS was used as the standard to study the application potential of targeted sequencing technology in neonatal screening and evaluate its consistency
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- shercru-20220003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborns
-
Fortaleza UniversityCompletedOrofacial Difficulties in Newborns | Maternal Breastfeeding in Newborns | Newborns in Rooming-in
-
Hospices Civils de LyonCompleted
-
Johnson & Johnson Consumer Inc. (J&JCI)University of SheffieldTerminated
-
Karadeniz Technical UniversityCompleted
-
Peking University Third HospitalUnknownEchocardiography of NewbornsChina
-
Groupe Hospitalier Paris Saint JosephCompletedNewborns | Delivery | MotherhoodFrance
-
University Hospital, MontpellierRecruitingIntensive Care | Newborns | NeonatologyFrance
-
University Hospital, MontpellierRecruitingSpinal Anesthesia | Infant | NewbornsFrance
-
LactaLogics, IncRenown Regional Medical CenterCompleted
-
Brigham and Women's HospitalUnknownParents of Healthy NewbornsUnited States
Clinical Trials on NGS
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants
-
Chang Gung Memorial HospitalRecruitingRecurrent Miscarriage | Chromosome Translocation | Genetic Disorders in PregnancyTaiwan
-
Rennes University HospitalCompleted
-
Yizhuo ZhangRecruitingPediatric, Solid Tumors, NGSChina
-
Karolinska University HospitalCompletedPancreatic Ductal Adenocarcinoma
-
Xianmin Song, MDRecruiting
-
Chinese Anti-Cancer AssociationUnknown
-
National Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | B-AllUnited States
-
The Belgian Society of Medical OncologyRoche Pharma AG; Foundation Medicine; SciensanoRecruiting
-
National Cancer Institute, NaplesRecruiting